Team:Slovenia/Project/Motivation





Track 2: Antigen-TLR fusion vaccine was designed to bypass the requirement of TLR agonists and provide the ability to trigger different signaling pathways or their combinations that result in antigen processing and presentation and production of a distinct set of costimulatory molecules. The main objective within this track was to prepare constructs with constitutively active Toll-like receptors that are:

fused to antigens,

localized within the activated endosomes,

where antigen is processed into peptides that are loaded to MHC II or

presented at cell surface to engage B-cell receptors while

TLR activation additionally provides costimulatory signals to neighboring cells. 